文献速递银屑病与炎症性皮肤病

生物制剂对银屑病患者心血管疾病影像与生物标志物的影响:随机安慰剂对照试验的系统综述与荟萃分析

Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
PubMed 文献 · J Invest Dermatol · 2021-04-21

该系统综述与荟萃分析纳入5项研究(其中2项进入荟萃分析),评估获批生物制剂对银屑病患者心血管疾病风险的影像学和血液生物标志物的影响。结果显示乌司奴单抗在12周时降低主动脉血管炎症,但52周时未维持;阿达木单抗和光疗可降低CRP和IL-6等血液标志物;阿达木单抗和司库奇尤单抗对影像学标志物无显著获益。

要点

  • 乌司奴单抗在12周降低主动脉血管炎症,但52周开放扩展期未维持。
  • 阿达木单抗和光疗可降低CRP、IL-6等血液 cardiometabolic 风险标志物。
  • 阿达木单抗和司库奇尤单抗对影像学标志物无显著改善。

核心结论

  • 随机对照试验显示乌司奴单抗降低主动脉血管炎症,TNF-α抑制剂和光疗降低CRP和IL-6。
  • 这些替代标志物发现需以心血管事件为终点的随机对照试验来指导临床实践。

研究设计与样本

  • 系统综述与荟萃分析,检索截至2020年6月1日的Medline-Ovid、EMBASE和CENTRAL数据库。
  • 最终纳入5项研究,其中2项进入荟萃分析。

主要发现

  • 与安慰剂相比,阿达木单抗在12-16周未显著降低主动脉血管炎症。
  • 与安慰剂相比,阿达木单抗和司库奇尤单抗对影像学标志物(主动脉血管炎症或血流介导的舒张)无有益影响。
  • 乌司奴单抗在12周降低主动脉血管炎症,但在52周开放扩展期后未维持降低。
  • 与安慰剂相比,阿达木单抗(CRP、TNF-α、IL-6和GlycA)和光疗(CRP和IL-6)观察到血液 cardiometabolic 风险标志物的最强降低。

临床怎么用

  • 生物制剂对心血管风险的替代标志物影响不一,不能仅凭此改变临床决策。
  • 需关注以心血管事件为终点的随机对照试验结果来指导银屑病患者的临床实践。

局限性

  • 仅5项研究纳入最终分析,其中2项进入荟萃分析,证据有限。
  • 替代标志物 findings 需心血管事件终点的随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of biologics on the risk for cardiovascular disease in patients with psoriasis is still unclear despite their widespread use. OBJECTIVE: The objective of this study was to examine the impact of licensed biological therapies on imaging and biomarkers of cardiovascular disease risk in patients with psoriasis by a systematic review and meta-analysis of placebo-controlled trials. METHODS: A comprehensive search of studies published before 1 June 2020 was performed in Medline-Ovid, EMBASE, and CENTRAL using a predefined strategy to identify relevant articles. RESULTS: Five studies were included for the final examination, and two studies were included in the meta-analysis. We did not find a significant reduction in aortic vascular inflammation in patients treated with adalimumab compared with those who received placebo at weeks 12-16. There was no beneficial effect on imaging biomarkers (aortic vascular inflammation or flow-mediated dilatation) of cardiovascular disease risk in patients exposed to biological therapies (adalimumab and secukinumab) compared with those exposed to placebo, except for ustekinumab showing a reduction in aortic vascular inflammation at week 12 but not at week 52 after the open-label extension period. The strongest reduction in blood-based cardiometabolic risk biomarkers was observed with adalimumab (CRP, TNF-α, IL-6, and GlycA) and phototherapy (CRP and IL-6) compared with that observed with placebo. CONCLUSIONS: Randomized controlled trials show that ustekinumab reduces aortic vascular inflammation and that TNF-α inhibitors and phototherapy reduce CRP and IL-6. These surrogate marker findings require randomized controlled trials evaluating cardiovascular events to inform clinical practice.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. González-Cantero A, Ortega-Quijano D, Álvarez-Díaz N, et al. Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. J Invest Dermatol. 2021. PMID: 33891953. doi:10.1016/j.jid.2021.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。